Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188211 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von JiHye Seo und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences & Biotechnology, College of Natural Sciences, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Cisplatin, Neoplastic Stem Cells, Lung Neoplasms, Trimebutine. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Daegu ANCHOR Center, Ministry of Education.
Abstract (Originalsprache)
Lung cancer recurrence and therapeutic resistance are driven by cancer stem cells (CSCs), yet clinically available CSC-targeted therapies remain lacking. To identify actionable anti-CSC agents, we screened 1018 FDA-approved drugs using a 3D sphere culture system enriching lung CSC-like cells. Trimebutine, a gastrointestinal motility regulator targeting G-protein-coupled receptors (GPCRs), was identified as a potent agent with over 49.5-fold higher selectivity toward lung CSC-like cells (SI > 49.55) compared with standard therapies such as cisplatin (SI = 1.39) and gefitinib (SI = 1.00). In H460-SP spheres, trimebutine markedly impaired sphere-forming capacity, reduced cell viability, and downregulated key CSC surface markers (CD133, CD44) alongside stemness regulators (c-MYC, EpCAM, BMI1, OCT3/4, NANOG, SOX2, SMAD3). Mechanistically, trimebutine suppressed overexpressed calcium and potassium channels (CACNA1F, CACNA1B, CACNA1E, CACNA1H, KCNH2), attenuating downstream YAP/TAZ–TEAD signaling within the Hippo pathway to trigger apoptosis. In combination with cisplatin, trimebutine exhibited strong synergistic efficacy (Chou–Talalay combination index, CI = 0.015–0.228) in H460-SP spheres and patient-derived lung tumor organoids, suppressing cell viability, stemness marker suppression, and apoptotic cleavage of caspase-3 and PARP compared to monotherapies. Overall, trimebutine targets lung CSC populations by disrupting GPCR–ion channel–Hippo signaling crosstalk, providing a strong preclinical rationale for trimebutine–cisplatin combination strategies to overcome drug resistance and recurrence in lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences & Biotechnology, College of Natural Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.
- Daegu ANCHOR Center, Kyungpook National University, Daegu 41566, Republic of Korea.
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu 41061, Republic of Korea.
- BK21 FOUR KNU Creative BioResearch Group, School of Life Science and Biotechnology, Kyungpook National University, Daegu 41566, Republic of Korea.
- Graduate School of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
- BK21 Infectious Disease Healthcare Program, Kyungpook National University, Daegu 41566, Republic of Korea.
ORCID-Profile: Jeong In Choi, Dong-Seok Lee
Förderung
- National Research Foundation of Korea
- Daegu ANCHOR Center
- Ministry of Education
Zitieren
APA
Seo, J., Lee, H., Choi, D. K., Kim, Y. K., Woo, S., Lee, C., Choi, J. I., Jiang, G., Oh, B. J., Lee, D. S., & Min, S. H. (2026). Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188211
Vancouver
Seo J, Lee H, Choi DK, Kim YK, Woo S, Lee C, et al. Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188211
BibTeX
@article{Seo2026,
author = {Seo, JiHye and Lee, Heejin and Choi, Dong Kyu and Kim, Young-Kyu and Woo, Somin and Lee, Changkyu and Choi, Jeong In and Jiang, Ge and Oh, Bae Jun and Lee, Dong-Seok and Min, Sang-Hyun},
title = {Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188211}
}
EUVIMED